Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) will provide a corporate update and report its financial results for Q1 2022 on May 5, 2022, after market close. Investors can access the results via a press release on the Vir website. The company focuses on immunologic therapies against infectious diseases, utilizing advanced technologies to boost the immune response. Its product pipeline includes candidates for COVID-19, hepatitis B, influenza A, and HIV.
- None.
- None.
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022.
The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
FAQ
When will Vir Biotechnology report its Q1 2022 financial results?
How can I access Vir Biotechnology's financial results?
What is the focus of Vir Biotechnology?
What diseases are included in Vir Biotechnology's development pipeline?
